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Managed care groups, physician management organiza-
tions, and independent practice associations in the United
States are increasingly seeing formulary submission
guidelines as a key management tool for cost and quality
control within health systems. The purpose of this work-
shop is to describe the process of guideline development,
the analytical and evaluative standards required from
those making submissions and the implementation of
guidelines within managed care health systems. The focus
is on the guidelines recently put in place by Blue Cross
Blue Shield of Colorado, Nevada, and New Mexico (with
over 0.5 million members), which were developed at the
University of Colorado, and similar guidelines in the pro-
cess of development for the Academy of Managed Care
Pharmacy in Washington, DC. Of particular importance
in this presentation are the analytical and evaluative stan-
dards required in the guidelines. While the guidelines are
similar in a number of respects to the revised November
1995 Australian guidelines, the central requirement is for
projections to be made of the net cost and outcomes im-
pact on a treating population from the introduction of a
new drug or therapy intervention in disease or treatment
areas. This is described as a systems impact assessment,
which is quite different from the analytical focus of tradi-
tional pharmaceutical economics. Rather than base for-
mulary decisions on implications drawn from synthetic
decision models, the guidelines ask for cost and outcome
impact assessments which are, in principle, verifiable.
This means they can serve as a basis for monitoring
health impact assessments of set targets and in the con-
text of disease or care management interventions.
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PRO AND CON: USE OF DATA FROM FOREIGN 
PHARMACOECONOMIC INVESTIGATIONS
IN RUSSIA
Stratchounski L, Rozenson O
Smolensk State Medical Academy, Smolensk, Russia
Pharmacoeconomic data are extremely useful for the de-
velopment of optimal treatment strategies in terms of clini-
cal efficacy, safety, and cost of drug therapy. Although sev-
eral pharmacoeconomic trials have been conducted in
Russia, these data are quite scarce in our country. In the
majority of cases, foreign data are the only available sources
of information. The main advantages of these data are
their methodology, design, and modern approaches to data
analyses and interpretation. However, Russian doctors
and health authorities should be very careful in using data
obtained abroad. As far as we are concerned, there are at
least four principal limitations for these data in Russia.
Firstly, variations in epidemiology of given diseases exist
among different countries. Secondly, we see a difference in
drug prices; for instance, cefotaxime (1 g) costs 2.44 USD
in Russia versus 11.7 USD in the US. Thirdly, the costs of
medical service and hospitalization are much less costly in
Russia than in Western countries—the cost per ICU day in
Russia is about 100 USD (Smolensk Regional Hospital),
whereas in the US it is about 1000 USD (Millard Fillmore
Suburban Hospital, Williamsville, NY). This may explain
to some extent the lack of sufficient attention paid by Rus-
sian physicians to the duration of hospitalization. The total
cost of treatment nowadays in Russia predominantly de-
pends on drug therapy cost. Finally, there are differences in
financing sources of health services between countries. The
Russian healthcare system is predominantly funded by the
Government and/or insurance companies. Moreover, there
are often different sources of financing within one region.
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Since 1998, the standardization system in Russia has been
functioning in the public health system, which corresponds
with the state system of standardization and with the inter-
national requirements in this field. This system is to solve
the following major problems: 1) to assure that citizens
shall exercise their rights to generally available free of
charge medical care of high quality; 2) to provide the com-
pulsory health insurance system in Russia with a standard-
izing base; and 3) to provide the certification and quality
assessment system to be set up in the health public system
with standards and specifications. At the first stage of de-
velopment, 16 groups of standardization objects were iden-
tified and the basic principles formulated. The most impor-
tant principles are a consensuality principle (i.e., a mutual
agreement between all the parties engaged in the develop-
ment and use of standards), an actuality principle (i.e.,
compliance of the elaborated documents with legislative
and other international and state requirements), and a com-
plexity principle (i.e., solution of problems of standard-
ization in all spheres of citizen healthcare by uniform
methods). At the second stage, a working program on the
establishment and development of a public health stan-
dardization system in Russia was worked out and ap-
proved, highlighting the priorities of work, defining a list of
priority regulatory documents, and executing this work.
Particular emphasis is placed on a group of system-forming
documents: a group of documents that regulate the terms,
conditions, and quality of the medical services rendered;
and a group of documents pertaining to drug provision,
medical equipment, informational technologies, etc. Assim-
ilation of the results of new studies in pharmacological
economy and evidence-based medicine will be a very im-
portant element of development of the documents regulat-
ing the rendering of medical services. The specialists of the
pharmaceutical company Rhône-Poulenc, whose collabora-
tion helps to introduce mathematical programs and infor-
mational technologies into the development of a program
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of standardization, were among the first to initiate new
pharmacoeconomic and pharmacoepidemiological devel-
opments. At the third stage, the establishment of a stan-
dardization service is envisaged. In addition to regulatory
documentation development proper, the service will be en-
gaged in putting these standards and specifications into
practice and in analyzing the results on the introduction of
specific regulatory documents. The I. M. Sechenov Moscow
Medical Academy (its Laboratory of Outcomes and Stan-
dardization Research Problems) has been appointed the
central research institution to deal with standardization
problems. It is entrusted with the duties of a coordinator of
research developments, an expert in the existing documents
and a developer of a standardizing base (now lacking). In
1999, a conference is to be held and a scientific journal cov-
ering standardization problems will begin publication.
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This workshop is intended for individuals with a basic un-
derstanding of the concepts and terminology of economic
evaluation of healthcare who want to discuss applied stan-
dardization methodologies. Several software tools are
available to assist in the development of pharmacoeco-
nomic models. However, the lack of a standardized set of
rules to present economic evaluation results may limit the
comparability of studies carried out by different analysts.
The objective of this session is to define a set of standard-
ized procedures to improve the comparability of results of
economic evaluation studies by means of user-friendly
computer software for Reporting Economic Evaluation
Results (the REER software). Two different prototypes
will be presented: an application aimed at presenting eco-
nomic evaluation results; and a health costs database
(HCD). The main program (REER) is divided into three
basic modules: 1) definition of options (treatment/interven-
tion comparators, subjects); 2) data inputs (resources, unit
costs, health outcomes, discounting and sensitivity analy-
sis); and 3) outputs (differences in costs and effects, domi-
nance analysis, incremental analysis, and sensitivity analy-
sis). A prototype version of the REER software will be
presented by means of two published pharmacoeconomic
analyses. The Health Costs Database Software (HCDS) en-
ables the collection, categorization, and storage of unit
cost data to be used in different types of studies (e.g., cost
analysis, economic evaluation). The database, which sim-
plifies the retrieval of average and actualized cost figures,
makes rapidly available updated unit cost data which can
be used directly (e.g., within the REER software), as a first
calculation, or can be contrasted with later cost estima-
tions. Problems with obtaining standardized results of eco-
nomic evaluation studies and the usefulness of programs
such as the REER software will be examined, and future
development of complete and fully operational software
tools will be discussed.
TRACK 3: QUALITY OF LIFE ASSESSMENT
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THE DARTS DIABETES DATABASE: HOW CAN 
QUALITY OF LIFE MEASUREMENTS FOR 
OUTCOMES RESEARCH BE INCORPORATED?
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The DARTS database is a validated, population-based reg-
ister of 9,000 patients with diabetes in the population of
Tayside, Scotland, compiled by the record-linkage of inde-
pendent datasets. These include diabetes clinic records,
hospital activity data, biochemistry results, and a database
of dispensed prescriptions. The database can be used for
epidemiological, outcomes, and health services research.
Diabetes is a disease with high morbidity and mortality,
for which treatments are onerous and time-consuming.
Thus the nonclinical or psychological dimension should
not be ignored, and so the incorporation of quality of life
measures into DARTS has been proposed. A wide range of
disease-specific and generic measures that tap into many
different facets of quality of life have already been used in
diabetes. The challenge is to identify a valid and reliable
package of measures that could be practical for the dia-
betic patients of Tayside. In this workshop, the approach
adopted to identify such a package for routine use in
DARTS will be described and discussed. It will include a
critical review of quality of life measures that have already
been used in diabetic patients, the results of a survey of di-
abetic patients and diabetic health professionals to identify
those aspects of quality of life deemed to be particularly
relevant to diabetes, and a discussion of the validation of
the measures chosen in a pilot group of patients. The
workshop would thus be of interest to researchers working
with quality of life outcome measures, and/or to those in-
volved in the development and application of disease-
specific databases.
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The measurement of a product’s intrinsic value has become
an essential part of a new technology’s reimbursement and
marketing strategy. The key tactics in the evaluation of a
